tradingkey.logo

Dyadic International Inc

DYAI
View Detailed Chart

1.070USD

+0.088+9.01%
Close 09/19, 16:00ETQuotes delayed by 15 min
32.25MMarket Cap
LossP/E TTM

Dyadic International Inc

1.070

+0.088+9.01%
Intraday
1m
30m
1h
D
W
M
D

Today

+9.01%

5 Days

+10.66%

1 Month

+35.41%

6 Months

-24.99%

Year to Date

-38.86%

1 Year

-10.08%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
216 / 506
Overall Ranking
346 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
9.000
Target Price
+816.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.50M.
Fairly Valued
The company’s latest PE is -5.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 14.22M shares, decreasing 0.47% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 860.66K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Ticker SymbolDYAI
CompanyDyadic International Inc
CEOMr. Mark A. Emalfarb
Websitehttps://dyadic.com/
KeyAI